{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T00:16:08Z","timestamp":1783728968072,"version":"3.55.0"},"reference-count":42,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"29","license":[{"start":{"date-parts":[[2023,7,21]],"date-time":"2023-07-21T00:00:00Z","timestamp":1689897600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,7,21]]},"abstract":"<jats:sec>\n                    <jats:title>Rationale:<\/jats:title>\n                    <jats:p>The morbidity and mortality of lung cancer rank the first among all kinds of cancer. In China, anaplastic lymphoma kinase-positive pulmonary tumors account for nearly 5% of non-small cell lung cancer (NSCLC), and these patients are quite likely to develop brain metastases, as high as around 45%. Although anaplastic lymphoma kinase-tyrosine kinase inhibitors crizotinib and alectinib have proved effective for controlling tumor metastases to the brain, drug resistance and disease progression cannot be ignored in the course of treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patient concerns:<\/jats:title>\n                    <jats:p>Most of the literature reports that traditional Chinese medicine (TCM) has produced satisfactory results in the treatment of cancer patients as an adjuvant treatment for various malignancies in a 53-year-old male patient who developed advanced NSCLC with brain metastases. As first-line crizotinib and erlotinib treatments were ineffective and the intracranial lesions progressed extensively, the patient chose to receive TCM treatment alone in the hope of prolonging his life and improving his quality of life.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Diagnoses:<\/jats:title>\n                    <jats:p>A 53-year-old male patient who developed advanced NSCLC with brain metastasis. Because first-line crizotinib and alectinib have failed, and the intracranial lesions progressed in a large area.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Interventions:<\/jats:title>\n                    <jats:p>The patient requested that the final therapeutic strategy be Chinese medicine as monotherapy for long-term treatment. The patient took 30\u2009mL of the decoction 1 hour after a meal, 3 times a day. The patient was not treated with dehydrating agents or diuretics during the TCM treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Outcomes:<\/jats:title>\n                    <jats:p>The improvement was obvious after 3 months of treatment, and significant reduction of cranial lesions. During the follow-up period, the patient developed neither severe liver damage nor kidney damage.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Lessons:<\/jats:title>\n                    <jats:p>This case is the first 1 in the world where TCM was introduced as monotherapy for severe conditions with extensive brain metastases and achieved remarkable efficacy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000034138","type":"journal-article","created":{"date-parts":[[2023,7,21]],"date-time":"2023-07-21T14:48:06Z","timestamp":1689950886000},"page":"e34138","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["TCM monotherapy achieves significant efficacy in crizotinib-refractory advanced NSCLC with brain metastasis"],"prefix":"10.1097","volume":"102","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-3479-9127","authenticated-orcid":false,"given":"Jiqiu","family":"Qin","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ru","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Ding","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lilai","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deliu","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-3836-7779","authenticated-orcid":false,"given":"Shaoquan","family":"Xiong","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260710","doi-asserted-by":"crossref","first-page":"2693","DOI":"10.1200\/JCO.2017.77.5841","article-title":"Exploratory analysis of brigatinib activity in patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer and brain metastases in two clinical trials.","volume":"36","author":"Camidge","year":"2018","journal-title":"J Clin Oncol"},{"key":"R2-20260710","doi-asserted-by":"crossref","first-page":"e342","DOI":"10.1016\/S1470-2045(15)00077-7","article-title":"Genomic alterations in lung adenocarcinoma.","volume":"16","author":"Devarakonda","year":"2015","journal-title":"Lancet Oncol"},{"key":"R3-20260710","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1056\/NEJMoa1408440","article-title":"First-line crizotinib versus chemotherapy in ALK-positive lung cancer.","volume":"371","author":"Solomon","year":"2014","journal-title":"N Engl J Med"},{"key":"R4-20260710","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1200\/JCO.2016.71.5904","article-title":"Brigatinib in patients with crizotinib-refractory anaplastic lymphoma kinase\u2013positive non\u2013small-cell lung cancer: a randomized, multicenter phase II trial.","volume":"35","author":"Kim","year":"2017","journal-title":"J Clin Oncol"},{"key":"R5-20260710","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa1704795","article-title":"Alectinib versus crizotinib in untreated ALK-Positive non-small-cell lung cancer.","volume":"377","author":"Peters","year":"2017","journal-title":"N Engl J Med"},{"key":"R6-20260710","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/S0140-6736(17)30123-X","article-title":"First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study.","volume":"389","author":"Soriya","year":"2017","journal-title":"Lancet"},{"key":"R7-20260710","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1016\/j.jtho.2018.06.012","article-title":"Results of PROFILE 1029, a Phase III comparison of First-line crizotinib versus chemotherapy in east asian patients with ALK-positive advanced non-small cell lung cancer.","volume":"13","author":"Wu","year":"2018","journal-title":"J Thorac Oncol"},{"key":"R8-20260710","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(17)30565-2","article-title":"Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial.","volume":"390","author":"Hida","year":"2017","journal-title":"Lancet"},{"key":"R9-20260710","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1200\/JCO.2014.59.0539","article-title":"Clinical experience with crizotinib in patients with advanced ALK-rearranged non-small-cell lung cancer and brain metastases.","volume":"33","author":"Costa","year":"2015","journal-title":"J Clin Oncol"},{"key":"R10-20260710","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1200\/JCO.2015.62.0138","article-title":"Extended survival and prognostic factors for patients with ALK-rearranged non-small-cell lung cancer and brain metastasis.","volume":"34","author":"Johung","year":"2016","journal-title":"J Clin Oncol"},{"key":"R11-20260710","doi-asserted-by":"crossref","first-page":"dju151","DOI":"10.1093\/jnci\/dju151","article-title":"Randomized trial of erlotinib plus whole-brain radiotherapy for NSCLC patients with multiple brain metastases.","volume":"106","author":"Lee","year":"2014","journal-title":"J Natl Cancer Inst"},{"key":"R12-20260710","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1097\/PPO.0000000000000126","article-title":"The biology of brain metastasis: challenges for therapy.","volume":"21","author":"Fidler","year":"2015","journal-title":"Cancer J"},{"key":"R13-20260710","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1093\/annonc\/mdy121","article-title":"Alectinib versus chemotherapy in crizotinib pretreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer: results from the phase III ALUR study.","volume":"29","author":"Novello","year":"2018","journal-title":"Ann Oncol"},{"key":"R14-20260710","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/S1470-2045(17)30339-X","article-title":"Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial.","volume":"18","author":"Shaw","year":"2017","journal-title":"Lancet Oncol"},{"key":"R15-20260710","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1007\/s11523-017-0510-9","article-title":"Targeting the PD-1\/PD-L1 immune checkpoint in EGFR ALK-translocated non-small-cell lung cancer.","volume":"12","author":"Bylicki","year":"2017","journal-title":"Target Oncol"},{"key":"R16-20260710","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/S2213-2600(17)30262-X","article-title":"Icotinib versus whole-brain irradiation in patients with EGFR-mutant non-small-cell lung cancer and multiple brain metastases (BRAIN): a multicentre, phase 3, open-label, parallel, randomised controlled trial.","volume":"5","author":"Yang","year":"2017","journal-title":"Lancet Respir Med"},{"key":"R17-20260710","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1002\/1097-0142(19810715)48:2<384::AID-CNCR2820480227>3.0.CO;2-8","article-title":"Intracerebral metastases in solid-tumor patients: natural history and results of treatment.","volume":"48","author":"Zimm","year":"1981","journal-title":"Cancer"},{"key":"R18-20260710","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1016\/S1470-2045(18)30649-1","article-title":"Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study.","volume":"19","author":"Solomon","year":"2018","journal-title":"Lancet Oncol"},{"key":"R19-20260710","doi-asserted-by":"crossref","first-page":"16","DOI":"10.5582\/bst.2015.01019","article-title":"The advantages of using traditional Chinese medicine as an adjunctive therapy in the whole course of cancer treatment instead of only terminal stage of cancer.","volume":"9","author":"Qi","year":"2015","journal-title":"Biosci Trends"},{"key":"R20-20260710","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1007\/s11655-019-3184-6","article-title":"Usage of Chinese herbs in cancer patients in southern China: a survey.","volume":"27","author":"Xiong","year":"2021","journal-title":"Chin J Integr Med"},{"key":"R21-20260710","doi-asserted-by":"crossref","first-page":"733e","DOI":"10.1007\/s11655-016-2737-1","article-title":"Comprehensive treatment with Chinese medicine in patients with advanced non-small cell lung cancer: a multicenter, prospective, cohort study.","volume":"23","author":"Liu","year":"2017","journal-title":"Chin J Integ Med"},{"key":"R22-20260710","doi-asserted-by":"crossref","DOI":"10.1177\/1534735419828836","article-title":"Chinese herbal medicine effectively prolongs the overall survival of pancreatic cancer patients: a case series.","volume":"18","author":"Wong","year":"2019","journal-title":"Integr Cancer Ther"},{"key":"R23-20260710","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","article-title":"FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.","volume":"364","author":"Conroy","year":"2011","journal-title":"N Engl J Med"},{"key":"R24-20260710","doi-asserted-by":"crossref","first-page":"129","DOI":"10.47102\/annals-acadmedsg.V39N2p129","article-title":"Complementary and alternative medicine among Singapore cancer patients.","volume":"39","author":"Chow","year":"2010","journal-title":"Ann Acad Med Singap"},{"key":"R25-20260710","first-page":"50","article-title":"Interactions between traditional Chinese medicines and western therapeutics.","volume":"13","author":"Chan","year":"2010","journal-title":"Curr Opin Drug Discov Devel"},{"key":"R26-20260710","doi-asserted-by":"crossref","first-page":"3153082","DOI":"10.1155\/2020\/3153082","article-title":"Therapeutic potential of diosgenin and its major derivatives against neurological diseases: recent advances.","volume":"2020","author":"Cai","year":"2020","journal-title":"Oxid Med Cell Longev"},{"key":"R27-20260710","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1142\/S0192415X11009354","article-title":"Evidence for improved neuropharmacological efficacy and decreased neurotoxicity in mice with traditional processing of Rhizoma Arisaematis.","volume":"39","author":"Huang","year":"2011","journal-title":"Am J Chin Med"},{"key":"R28-20260710","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1007\/s10616-017-0102-7","article-title":"Molecular mechanisms of Bombyx batryticatus ethanol extract inducing gastric cancer SGC-7901 cells apoptosis.","volume":"69","author":"Wu","year":"2017","journal-title":"Cytotechnology"},{"key":"R29-20260710","first-page":"1540","article-title":"Cancer cell","volume":"56","author":"Kim","year":"2020","journal-title":"Int J Oncol"},{"key":"R30-20260710","first-page":"67","article-title":"The inhibitory effect of extracts from Fructus lycii and Rhizoma polygonati on in vitro DNA breakage by alternariol.","volume":"9","author":"Xu","year":"1996","journal-title":"Biomed Environ Sci"},{"key":"R31-20260710","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1002\/ptr.3265","article-title":"Fructus ligustri lucidi extracts induce human glioma cell death through regulation of Akt\/mTOR pathway in vitro and reduce glioma tumor growth in U87MG xenograft mouse model.","volume":"25","author":"Jeong","year":"2011","journal-title":"Phytother Res"},{"key":"R32-20260710","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1016\/S0008-6215(03)00073-9","article-title":"Structural elucidation and antitumor activity of a fructan from Cyathula officinalis Kuan.","volume":"338","author":"Chen","year":"2003","journal-title":"Carbohydr Res"},{"key":"R33-20260710","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1142\/S0192415X16500014","article-title":"Astragalus membranaceus: a review of its protection against inflammation and gastrointestinal cancers.","volume":"44","author":"Auyeung","year":"2016","journal-title":"Am J Chin Med"},{"key":"R34-20260710","doi-asserted-by":"crossref","first-page":"9206951","DOI":"10.1155\/2019\/9206951","article-title":"The combination of astragalus membranaceus and angelica sinensis inhibits lung cancer and cachexia through its immunomodulatory function.","volume":"2019","author":"Wu","year":"2019","journal-title":"J Oncol"},{"key":"R35-20260710","first-page":"1164","article-title":"Anti-mutagenesis effects of total flavonoids of Astragalus].","volume":"28","author":"Wang","year":"2003","journal-title":"Zhongguo Zhong Yao Za Zhi"},{"key":"R36-20260710","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1002\/jssc.201801262","article-title":"Screening and isolation of cyclooxygenase-2 inhibitors from the stem bark of phellodendron amurense Ruprecht by ultrafiltration with liquid chromatography and tandem mass spectrometry, and complex chromatography.","volume":"42","author":"Li","year":"2019","journal-title":"J Sep Sci"},{"key":"R37-20260710","first-page":"5261","article-title":"Growth inhibitory efficacy of Cornus officinalis in a cell culture model for triple-negative breast cancer.","volume":"17","author":"Telang","year":"2019","journal-title":"Oncol Lett"},{"key":"R38-20260710","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1142\/S0192415X17500203","article-title":"Antitumor and immunomodulatory effect of gastrodia elata on colon cancer in vitro and in vivo.","volume":"45","author":"Kim","year":"2017","journal-title":"Am J Chin Med"},{"key":"R39-20260710","doi-asserted-by":"crossref","first-page":"7561","DOI":"10.7314\/APJCP.2015.16.17.7561","article-title":"Dietary Ziziphus jujuba fruit influence on aberrant crypt formation and blood cells in colitis-associated colorectal cancer in mice.","volume":"16","author":"Periasamy","year":"2015","journal-title":"Asian Pac J Cancer Prev"},{"key":"R40-20260710","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.ijbiomac.2020.06.054","article-title":"A pectin-like polysaccharide from Polygala tenuifolia inhibits pancreatic cancer cell growth in vitro and in vivo by inducing apoptosis and suppressing autophagy.","volume":"162","author":"Bian","year":"2020","journal-title":"Int J Biol Macromol"},{"key":"R41-20260710","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1002\/tox.22577","article-title":"Antimetastatic effects of Eclipta prostrata extract on oral cancer cells.","volume":"33","author":"Liao","year":"2018","journal-title":"Environ Toxicol"},{"key":"R42-20260710","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.jconrel.2018.08.026","article-title":"Dual-targeted casein micelles as green nanomedicine for synergistic phytotherapy of hepatocellular carcinoma.","volume":"287","author":"Abdelmoneem","year":"2018","journal-title":"J Control Release"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000034138","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T00:01:06Z","timestamp":1783728066000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000034138"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,21]]},"references-count":42,"journal-issue":{"issue":"29","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000034138","relation":{},"ISSN":["0025-7974"],"issn-type":[{"value":"0025-7974","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7,21]]}}}